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Abstract. This paper applies risk analysis to medical problems, through
the properties of nonlinear responses (convex or concave). It shows 1)
necessary relations between the nonlinearity of dose-response and the sta-
tistical properties of the outcomes, particularly the effect of the variance
(i.e., the expected frequency of the various results and other properties
such as their average and variations); 2) The description of ”antifragility”
as a mathematical property for local convex response and its generaliza-
tion and the designation ”fragility” as its opposite, locally concave; 3)
necessary relations between dosage, severity of conditions, and iatrogen-
ics.
Iatrogenics seen as the tail risk from a given intervention can be an-
alyzed in a probabilistic decision-theoretic way, linking probability to
nonlinearity of response. There is a necessary two-way mathematical re-
lation between nonlinear response and the tail risk of a given intervention.
In short we propose a framework to integrate the necessary consequences
of nonlinearities in evidence-based medicine and medical risk manage-
ment.
Keywords: evidence based medicine, risk management, nonlinear re-
sponses
Comment on the notations : we use x for the dose, S(x) for the response function
to x when is sigmoidal (or was generated by an equation that is sigmoidal), and
f(x) when it is not necessarily so.
1 Background
Consideration of the probabilistic dimension has been made explicitly in some
domains, for instance there are a few papers linking Jensen’s inequality and noise
in pulmonary ventilators: papers such as Brewster et al. (2005)[1], Graham et
al.(2005) [2], Funk (2004)[3], Arold et al. (2003)[4], Mutch et al. (2007), Amato et
al. [5]. In short, to synthesize the literature, continuous high pressures have been
shown to be harmful with increased mortality, but occasional spikes of ventilation
pressures can be advantageous with recruitment of collapsed alveoli, and do
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Fig. 1. These two graphs summarize the gist of this chapter: how we can go from the
reaction or dose-response S(x), combined with the probability distribution of x, to the
probability distribution of S(x) and its properties: mean, expected benefits or harm,
variance of S(x). Thus we can play with the different parameters affecting S(x) and
those affecting the probability distribution of x, to assess results from output. S(x) as
we can see can take different shapes (We start with S(x) monotone convex (top) or
the second order sigmoid).
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not cause further increased mortality. But explicit probabilistic formulations are
missing in other domains, such as episodic energy deficit, intermittent fasting,
variable uneven distribution of sub-groups ( proteins and autophagy), vitamin
absorption, high intensity training, fractional dosage, the comparative effects of
chronic vs actute, moderate and distributed vs intense and concentrated, etc.
Further, the detection of convexity is still limited to local responses and does
not appear to have led to decision-making under uncertainty and inferences on
unseen risks based on the detection of nonlinearity in response, for example the
relation between tumor size and the iatrogenics of intervention, or that between
the numbers needed to treat and the side effects (visible and invisible) from an
intervention such as statins or various blood pressure treatments.
The links we are investigating are mathematical and necessary. And they are
two-way (work in both directions). To use a simple illustrative example:
– a convex response of humans to energy balance over a time window neces-
sarily implies the benefits of intermittent fasting (seen as higher variance in
the distribution of nutrients) over some range that time window,
– the presence of misfitness in populations that have exceedingly steady nu-
trients, and evidence of human fitness to an environment that provides high
variations (within bounds) in the availability of food, both necessarily im-
ply a nonlinear (concave) response to food over some range of intake and
frequency (time window).
The point can be generalized in the same manner to energy deficits and the
variance of the intensity of such deficits given a certain average.
Note the gist of our approach: we are not asserting that the benefits of in-
termittent fasting or the existence of a convex response are true; we are just
showing that if one is true then the other one is necessarily so, and building
decision-making policies that bridge the two.
Finally, note that convexity in medicine is at two levels. First, understanding
the effect of dosing and its nonlinearity. Second, at the level of risk analysis for
patients.
1.1 Convexity and its Effects
Let us define convexity as follows. Let the ”response” function f : R+ → R be a
twice differentiable function. If over a range x ∈ [a, b], over a set time period ∆t,
∂2f(x)
∂x2 ≥ 0, or more practically (by relaxing the assumptions of differentiability),
1
2 (f(x+∆x) + f(x−∆x)) ≥ f(x), with x+∆x and x−∆x ∈ [a, b] then there
are benefits or harm from the unevenness of distribution, pending whether f is
defined as positive or favorable or modeled as a harm function (in which case
one needs to reverse the sign for the interpretation).
In other words, in place of a dose x, one can give, say, 140% of x, then
60% of x, with a more favorable outcome one is in a zone that benefits from
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unevenness. Further, more unevenness is more beneficial: 140% followed by 60%
produces better effects than, say, 120% followed by 80%.
We can generalize to comparing linear combinations:
∑
αi = 1, 0 ≤ |αi| ≤ 1,∑
(αif(xi)) ≥ f(
∑
(αixi)); thus we end up with situations where, for x ≤ b−∆
and n ∈ N, f(nx) ≥ nf(x). This last property describes a ”stressor” as having
higher intensity than zero: there may be no harm from f(x) yet there will be
one at higher levels of x.
Now if X is a random variable with support in [a, b] and f is convex over the
interval as per above, then
E (f(x)) ≥ f (E(x)) , (1)
what is commonly known as Jensen’s Inequality, see Jensen(1906) [6], Fig. 2.
Further (without loss of generality), if its continuous distribution with density
ϕ(x) and support in [a, b] belongs to the location scale family distribution, with
ϕ( xσ ) = σϕ(x) and σ > 0, then, with Eσ the indexing representing the expecta-
tion under a probability distribution indexed by the scale σ, we have:
∀σ2 > σ1, Eσ2 (f(x)) ≥ Eσ1 (f(x)) (2)
The last property implies that the convexity effect increases the expectation
operator. We can verify that since
∫ f(b)
f(a)
y
φ(f(−1)(y))
f ′(f(−1)(y))
dy is an increasing function
of σ. A more simple approach (inspired from mathematical finance heuristics)
is to consider for 0 ≤ δ1 ≤ δ2 ≤ b − a, where δ1 and δ2 are the mean expected
deviations or, alternatively, the results of a simplified two-state system, each
with probability 12 :
f(x− δ2) + f(x+ δ2)
2
≥ f(x− δ1) + f(x+ δ1)
2
≥ f(x) (3)
This is of course a simplification here since dose response is rarely monotone
in its nonlinearity, as we will see in later sections. But we can at least make
claims in a certain interval [a, b].
What are we measuring? Clearly, the dose (represented on the x line) is hardly
ambiguous: any quantity can do, such as pressure, caloric deficit, pounds per
square inch, temperature, etc.
The response, harm or benefits, f(x) on the other hand, need to be equally
precise, nothing vague, such as life expectancy differential, some index of health,
and similar quantities. If one cannot express the response quantitatively, then
such an analysis cannot apply.
1.2 Antifragility
We define as locally antifragile1 a situation in which, over a specific interval
[a, b], either the expectation increases with the scale of the distribution as in
1 The term antifragile was coined in Taleb (2012) [7] inspired from mathematical
finance and derivatives trading, by which some payoff functions respond positively
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Dose
Response f
fHxL
f Hx+DxL+ f Hx-DxL
2
H
Fig. 2. Jensen’s inequality
Constant
Excess over
threshold
0.5
1.0
1.5
2.0
Fig. 3. The figure shows why fractional intervention can be more effective in exceeding
a threshold than constant dosage. This effect is similar to stochastic resonance
known in physics by which noise cause signals to rise above the threshold of detection.
For instance, genetically modified BT crops produce a constant level of pesticide, which
appears to be much less effective than occasional manual interventions to add doses to
conventional plants. The same may apply to antibiotics, chemotherapy and radiation
therapy.
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Higher
variance(red)
Lower 
variance(orange)
Intensity
Two distributions of the same mean
Fig. 4. An illustration of how a higher variance (hence scale), given the same mean,
allow more spikes –hence an antifragile effect. We have a Monte Carlo simulations
of two gamma distribution of same mean, different variances, X1 ∼ G(1, 1) and X2 ∼
G( 1
10
, 10), showing higher spikes and maxima for X2. The effect depends on norm ||.||∞
, more sensitive to tail events, even more than just the scale which is related to the
norm ||.||2.
1.0 1.5 2.0 2.5 3.0
σ
0.05
0.10
0.15
P>K
Fig. 5. Representation of Antifragility of Fig. 4 in distribution space: we show the
probability of exceeding a certain threshold for a variable, as a function of σ the scale
of the distribution, while keeping the mean constant.
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Threshold (can be seen
as sigmoid)Increasingvariance
Increases 
pr of exceeding
threshold
Exceeding
threshold
S(x)
x
Fig. 6. How an increase in variance affects the threshold. If the threshold is above the
mean, then we are in the presence of convexity and variance increases expected payoff
more than changes in the mean, in proportion of the remoteness of the threshold. Note
that the tails can be flipped (substituting the left for the right side) for the harm
function if it is defined as negative.
Eq. 2, or the dose response is convex over the same interval. The term in Taleb
(2012) [7] was meant to describe such a situation with precision: any situation
that benefits from an increase in randomness or variability (since σ, the scale of
the distribution, represents both); it is meant to be more precise than the vague
”resilient” and bundle behaviors that ”like” variability or spikes. Fig. 3, 4, 5 and
6 describe the threshold effect on the nonlinear response, and illustrates how
they qualify as antifragile.
1.3 The first order sigmoid curve
Define the sigmoid or sigmoidal function as having membership in a class of
function S, S : R → [L,H], with additional membership in the C2 class (twice
differentiable), monotonic nonincreasing or nondecreasing, that is let S′(x) be
the first derivative with respect to x: S′(x) ≥ 0 for all x or S′(x) ≤ 0. We have:
S(x) =
{
H as x→ +∞;
L if x→ −∞. ,
to increase in volatility and other measures of variation, a term in the vernacular
called ”long gamma”.
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which can of course be normalized withH = 1 and L = 0 if S is increasing, or vice
versa, or alternatively H = 0 and L = −1 if S is increasing. We can define the
simple (or first order) sigmoid curve as having equal convexity in one portion
and concavity in another: ∃k > 0 s.t. ∀x1 < k and x2 > k, sgn (S′′(x1)) =
−sgn(S′′(x2)) if |S′′(x2)| ≥ 0.
Now all functions starting at 0 will have three possible properties at inception,
as in Fig. 8:
– concave
– linear
– convex
The point of our discussion is the latter becomes sigmoid and is of interest to
us. Although few medical examples appear, under scrutiny, to belong to the first
two cases, one cannot exclude them from analysis. We note that given that the
inception of these curves is 0, no linear combination can be initially convex unless
the curve is convex, which would not be the case if the start of the reaction is
at level different from 0.
[h!]
There are many sub-classes of functions producing a sigmoidal effect. Exam-
ples:
– Pure sigmoids with smoothness characteristics expressed in trigonometric or
exponential form, f : R→ [0, 1]:
f(x) =
1
2
tanh
(κx
pi
)
+
1
2
f(x) =
1
1− e−ax
– Gompertz functions (a vague classification that includes above curves but
can also mean special functions )
– Special functions with support in R such as the Error function f : R→ [0, 1]
f(x) = −1
2
erfc
(
− x√
2
)
– Special functions with support in [0, 1], such as f : [0, 1]→ [0, 1]
f(x) = Ix(a, b),
where I(.)(., .) is the Beta regularized function.
– Special functions with support in [0,∞)
f(x) = Q
(
a, 0,
x
b
)
where Q (., ., .) is the gamma regularized function.
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x
0.2
0.4
0.6
0.8
1.0
f(x)
x
-1.0
-0.8
-0.6
-0.4
-0.2
f(x)
Fig. 7. Simple (first order) nonincreasing or nondecreasing sigmoids
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1-concave
2-linear
3-convex
At inception
Initial dose
0 Dose
Response
Fig. 8. The three possibilities at inception
– Piecewise sigmoids, such as the CDF of the Student Distribution
f(x) =

1
2I αx2+α
(
α
2 ,
1
2
)
x ≤ 0
1
2
(
I x2
x2+α
(
1
2 ,
α
2
)
+ 1
)
x > 0
We note that the ”smoothing” of the step function, or Heaviside theta θ(.)
produces to a sigmoid (in a situation of a distribution or convoluted with a test
function with compact support), such as 12 tanh
(
κx
pi
)
+ 12 , with κ→∞, see Fig.
12.
1.4 Some necessary relations leading to a sigmoid curve
Let f1(x) : R+ → [0, H] , H ≥ 0, of class C2 be the first order dose-response
function, satisfying f1(0) = 0, f
′
1(0)| = 0, limx→+∞ f1(x) = H, monotonic
nondecreasing, that is, f ′1(x) ≥ 0 ∀x ∈ R+, with a continuous second derivative,
and analytic in the vicinity of 0. Then we conjecture that:
A- There is exist a zone [0, b] in which f1(x) is convex, that is f
′′
1 (x) ≥ 0, with
the implication that ∀a ≤ b a policy of variation of dosage produces beneficial
effects:
αf1(a) + (1− α)f1(b) ≥ f1(αa+ (1− α)b), 0 ≤ α ≤ 1.
(The acute outperforms the chronic).
B- There is exist a zone [c,H] in which f1(x) is concave, that is f
′′
1 (x) ≤ 0,
with the implication that ∃d ≥ c a policy of stability of dosage produces beneficial
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a
bConvex zone
0 Dose
Response
Fig. 9. Every (relatively) smooth dose-response with a floor has to be convex, hence
prefers variations and concentration
Concave zonec
d
H
Dose
Response
Fig. 10. Every (relatively) smooth dose-response with a ceiling has to be concave,
hence prefers stability
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S2(x, 1, -2, 1, 2, 1, -7.5)
S2(x, 1, -2, 1, 2, 1, -15)
S2x, 1, -1, 3
2
, 2, 1, -11
S1(x, 1, 1, 0)
Dose
-1.0
-0.5
0.5
1.0
Response
Fig. 11. The Generalized Response Curve, S2 (x; a1, a2, b1, b2, c1, c2) , S
1 (x; a1, b1, c1)
The convex part with positive first derivative has been designated as ”antifragile”
Converges to 
Heaviside θ(x-K)
at point K
0.2
0.4
0.6
0.8
1.0
Fig. 12. The smoothing of Heaviside as distribution or Schwartz function; we can treat
step functions as sigmoid so long as K, the point of the step, is different from origin
or endpoint.
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effects:
αf1(c) + (1− α)f1(d) ≤ f1(αc+ (1− α)d).
(The chronic outperforms the acute).
2 The Generalized Dose Response Curve
Let SN (x): R→ [kL, kR], SN ∈ C∞, be a continuous function possessing deriva-
tives
(
SN
)(n)
(x) of all orders, expressed as an N -summed and scaled standard
sigmoid functions:
SN (x) ,
N∑
i=1
ak
1 + e(−bkx+ck)
(4)
where ak, bk, ck are scaling constants ∈ R, satisfying:
i) SN (-∞) =kL
ii) SN (+∞) =kR
and (equivalently for the first and last of the following conditions)
iii) ∂
2SN
∂x2 ≥ 0 for x ∈ (-∞, k1) , ∂
2SN
∂x2 < 0 for x ∈ (k2, k>2), and ∂
2SN
∂x2 ≥ 0 for
x ∈ (k>2, ∞), with k1 > k2 ≥ . . . ≥ kN .
By increasingN , we can approximate a continuous functions dense in a metric
space, see Cybenko (1989) [8].
The shapes at different calibrations are shown in Fig. 11, in which we com-
bined different values of N=2 S2 (x; a1, a2, b1, b2, c1, c2) , and the standard sig-
moid S1 (x; a1, b1, c1), with a1=1, b1=1 and c1=0. As we can see, unlike the
common sigmoid , the asymptotic response can be lower than the maximum,
as our curves are not monotonically increasing. The sigmoid shows benefits in-
creasing rapidly (the convex phase), then increasing at a slower and slower rate
until saturation. Our more general case starts by increasing, but the reponse can
be actually negative beyond the saturation phase, though in a convex manner.
Harm slows down and becomes ”flat” when something is totally broken.
3 Antifragility in the various literatures
Before moving to the iatrogenics section, let us review the various literature that
found benefits in increase in scale (i.e. local antifragility) though without gluing
their results as part of a general function.
In short the papers in this section show indirectly the effects of an increase in
σ for diabetes, alzheimer, cancer rates, or whatever condition they studied. The
scale of the distribution means increasing the variance, say instead of giving a
feeding of x over each time step ∆t, giving x− δ then x+ δ instead, as in Eqs.
1 and 2. Simply, intermittent fasting would be having ∆ ≈ x. and the scale can
be written in such a simplified example as the dispersion σ ≈ δ.
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3.1 Denial of second order effect
In short, antifragility is second order effect (the average is the first order effect).
One blatant mistake in the literature lies in ignoring the second order effect
when making statements from empirical data. An illustration is dietary recom-
mendations based on composition without regard to frequency. For instance, the
use of epidemiological data concerning the Cretan diet focused on composition
and not how often people ate each food type. Yet frequency matters: the Greek
Orthodox church has, depending on the severity of the local culture, almost two
hundred vegan days per year, that is, an episodic protein deprivation; meats
are eaten in lumps that compensate for the deprivation. As we will see with
the literature below, there is a missing mathematical bridge between studies of
variability, say Mattson et al.(2006) and Fontana et al (2008) on one hand, and
the focus on food composition –the Longo and Fontana studies, furthermore,
narrows the effect of the frequency to a given food type, namely proteins2.
Further, the computation of the ”recommended daily” units may vary markedly
if one assumes second order effects: the needed average is mathematically sensi-
tive to frequency, as we saw earlier.
3.2 Scouring the literature for antifragility
A sample of papers document such reaction to σ is as follows.
Mithridatization and hormesis: Kaiser (2003) [11] (see Fig. 13), Rattan (2008)
[12], Calabrese and Baldwin (2002, 2003a, 2003b) [13],[14],[15], Aruguman et
al (2006) [16]. Note that the literature focuses on mechanisms and misses the
explicit convexity argument. Is also absent the idea of divergence from, or con-
vergence to the norm –hormesis might just be reinstatement of normalcy as we
will discuss further down.
Caloric restriction and hormesis: Martin, Mattson et al. (2006) [17].
Treatment of various diseases: Longo and Mattson(2014) [18].
Cancer treatment and fasting: Longo et al. (2010) [19], Safdie et al. (2009) [20],
Raffaghelo et al. (2010), [21], Lee et al (2012) [22].
Aging and intermittence: Fontana et al. [23].
For brain effects: Anson, Guo, et al. (2003) [24], Halagappa, Guo, et al. (2007)
[25], Stranahan and Mattson (2012) [26]. The long-held belief that the brain
needed glucose, not ketones, and that the brain does not go through autophagy,
has been progressively replaced.
2 Lee and Longo (2011) [9] ”In the prokaryote E. coli, lack of glucose or nitrogen
(comparable to protein restriction in mammals) increase resistance to high levels of
H2O2 (15 mm) (Jenkins et al., 1988) [10]”
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Fig. 13. Hormesis in Kaiser (2003) we can detext a convex-concave sigmoidal shape
that fits our generalized sigmoid in Eq.4.
On yeast and longevity under restriction; Fabrizio et al. (2001)[27]; SIRT1,
Longo et al. (2006) [28], Michan et al. (2010) [29].
For diabetes, remission or reversal: Taylor (2008) [30], Lim et al. (2011) [31],
Boucher et al. (2004) [32]; diabetes management by diet alone, early insights
in Wilson et al. (1980) [33]. Couzin (2008) [34] gives insight that blood sugar
stabilization does not have the effect anticipated (which in our language implies
that σ matters). The ACCORD study (Action to Control Cardiovascular Risk in
Diabetes) found no gain from lowering blood glucose, or other metrics –indeed,
it may be more opaque than a simple glucose problem remedied by pharmaco-
logical means. Synthesis, Skyler et al. (2009) [35], old methods, Westman and
Vernon (2008) [36]. Bariatric (or other) surgery as an alternative approach from
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intermittent fasting: Pories (1995) [37], Guidone et al. (2006) [38], Rubino et al.
2006 [39].
Ramadan and effect of fasting: Trabelsi et al. (2012) [40], Akanji et al. (2012).
Note that the Ramadan time window is short (12 to 17 hours) and possibly
fraught with overeating so conclusions need to take into account energy balance
and that the considered effect is at the low-frequency part of the timescale.
Caloric restriction: Harrison (1984), Wiendruch (1996), Pischon (2008). An un-
derstanding of such natural antifragility can allow us to dispense with the far
more speculative approach of pharmalogical interventions such as suggested in
Stip (2010) –owing to more iatrogenics discussed in the next section4.
Autophagy for cancer: Kondo et al. (2005) [41].
Autophagy (general): Danchin et al. (2011) [42], He et al. (2012) [43].
Fractional dosage: Wu et al. (2016) [44]. Jensen’s inequality in workout: Many
such as Schnohr and Marott (2011) [45] compare the results of intermittent
extremes with ”moderate” physical activity; they got close to dealing with the
fact that extreme sprinting and nothing outperforms steady exercise, but missed
the convexity bias part.
Cluster of ailments: Yaffe and Blackwell (2004) [46], Alzheimer and hyperinsu-
lenemia as correlated, Razay and Wilcock (1994) [47]; Luchsinger, Tang, et al.
(2002) [48], Luchsinger Tang et al. (2004) [49] Janson, Laedtke, et al. (2004) [50].
The clusters are of special interest as they indicate how the absence or presence
of convex effect can manifest itself in multiple diseases.
Benefits of some type of stress (and convexity of the effect): For the different
results from the two types of stressors, short and chronic, Dhabar (2009) ”A
hassle a day may keep the pathogens away: the fight-or-flight stress response
and the augmentation of immune function” [51]. for the benefits of stress on
boosting immunity and cancer resistance (squamous cell carcinoma), Dhabhar
et al. (2010) [52], Dhabhar et al. (2012) [53] , Ansbacher et al. (2013)[54].
Iatrogenics of hygiene and systematic elimination of germs: Rook (2011) [55],
Rook (2012) [56] (auto-immune diseases from absence of stressor), Me´graud and
Lamouliatte (1992) [57] for Helyobacter Pilori and incidence of cancer.
3.3 Extracting an ancestral frequency
We noted that papers such as Kaiser (2003) [11] and Calabrese and Baldwin
(2003) , [14] miss the point that hormesis may correspond to a ”fitness dose”,
beyond and below which one departs from such ideal dispersion of the dose x
per time period.
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We can also apply the visible dose-response curve to inferring the ideal
parametrization of the probability distribution for our feeding (ancestral or oth-
erwise) and vice-versa. For instance, measuring the effects of episodic fasting on
cancer, diabetes, and other ailments can lead to assessing some kind of ”fitness”
to an environment with a certain structure of randomness, either with the σ
above or some richer measure of probability distribution. Simply, if diabetes can
be controlled or reversed with occasional deprivation (a certain variance), say 24
hour fasts per week, 3 days per quarter, and a full week every four years, then
necessarily our system can be made to fit stochastic energy supply, with a cer-
tain frequency of deficits –and, crucially, we can extract the functional expression
from such frequencies.
Note that an understanding of the precise mechanism by which intermittence
works (whether dietary or in energy expenditure), which can be autophagy or
some other mechanism such as insulin control, are helpful but not needed given
the robustness of the mathematical link between the functional and the proba-
bilistic.
4 Nonlinearities and Iatrogenics
ξ(K,s-) = ∫-∞K (x - Ω) pλ(s-) (x)ⅆx
ξ K, s- + Δs-) = -∞K (x - Ω) pλ(s-+Δs-) (x)ⅆx
K
x
p density
Fig. 14. A definition of fragility as left tail payoff sensitivity; the figure shows the
effect of the perturbation of the lower semi-deviation s− on the tail integral ξ of (x−Ω)
below K, Ω being a centering constant. Our detection of fragility does not require the
specification of p the probability distribution.
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Next we connect nonlinearity to iatrogenics, broadly defined as all manner
of net deficit of benefits minus harm from a given intervention.
In short, Taleb and Douady (2013) [58] describes fragility as a ”tail” property,
that is, below a set level K, how either 1) greater uncertainty or 2) more vari-
ability translate into a degradation of the effect of the probability distribution
on the expected payoff.
The probability distribution of concern has for density p, a scale s− for the
distribution below Ω a centering constant (we can call s− a negative semidevia-
tion). To cover a broader set of distributions, we use pλ(s) where λ is a function
of s.
We set ξ(., .) a function of the expected value below K. Intuitively it is meant
to express the harm, and, mostly its variations –one may not have a precise idea
of the harm but the variations can be extracted in a more robust way.
ξ(s−) =
∫ K
−∞
|x−Ω| pλ(s−)(x) dx (5)
ξ(s− +∆s−) =
∫ K
−∞
|x−Ω| pλ(s−+∆s−)(x) dx (6)
Fragility is defined as the variations of ξ(.) from an increase in the left scale
s− as shown in Fig 14. The difference ξ(∆s−) represents a sensitivity to an
expansion in uncertainty in the left tail.
The theorems in Taleb and Douady (2013) [58] show that:
– Convexity in a dose-response function increases ξ.
– Detecting such nonlinearity allows us to predict fragility and formulate a
probabilistic decision without knowing p(.).
– The mere existence of concavity in the tails implies an unseen risk.
4.1 Effect reversal and the sigmoid
Now let us discuss Figs. 15 and 16. The nonlinearities of dose response and
hormetic or neutral effect at low doses is illustrated in the case of radiation:
In Neumaier et al. (2012) [59] titled ”Evidence for formation of DNA repair
centers and dose-response nonlinearity in human cells”, the authors write: ”The
standard model currently in use applies a linear scale, extrapolating cancer risk
from high doses to low doses of ionizing radiation. However, our discovery of
DSB clustering over such large distances casts considerable doubts on the general
assumption that risk to ionizing radiation is proportional to dose, and instead
provides a mechanism that could more accurately address risk dose dependency
of ionizing radiation.” Radiation hormesis is the idea that low-level radiation
causes hormetic overreaction with protective effects. Also see Tubiana et al.
(2005) [60].
Bharadwaj and Stafford (2010) present similar general-sigmoidal effects in
hormonal disruptions by chemicals [61].
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Medical Breakeven
Iatrogenics zone
Condition
Drug Benefit
Fig. 15. Drug benefits when convex to Numbers Needed to Treat, with gross iatrogenics
invariant to condition (the constant line). We are looking at the convex portion of a
possibly sigmoidal benefit function.
Iatrogenics
Treatment 
breakeven 
Tumor Size
Severity
Fig. 16. Tumor breakeven we consider a wider range of Fig. 15 and apply it to the
relation between tumor size and treatment breakeven.
20 Nassim Nicholas Taleb
Outcomes
Probability
Hidden Iatrogenics Benefits
Fig. 17. Unseen risks and mild gains: translation of Fig. 15 to the skewness of a decision
involving iatrogenics when the condition is mild. This also illustrates the Taleb and
Douady[58] translation theorems from concavity for S(x) into a probabilistic attributes.
4.2 Nonlinearity of NNT, overtreatment, and decision-making
Below are applications of convexity analysis in decision-making in dosage, shown
in Fig. 15, 16 and Fig. 17.
In short, it is fallacious to translate a policy derived from acute conditions
and apply it to milder ones. Mild conditions are different in treatment from an
acute one.
Likewise, high risk is qualitatively different from mild risk.
Mammogram controversy There is an active literature on ”overdiagnosis”,
see Kalager et al(2012) [62], Morell et al.(2012) [63]. The point is that treating
a tumor that doesn’t kill reduces life expectancy; hence the need to balance
iatrogenics and risk of cancer. An application of nonlinearity can shed some
light to the approach, particularly that public opinion might find it ”cruel” to
deprive people of treatment even if it extends their life expectancy [7].
Hypertension illustrations Consider the following simplified case from blood
pressure studies: assume that when hypertension is mild, say marginally higher
than the zone accepted as normotensive, the chance of benefiting from a certain
drug is close to 5% (1 in 20). But when blood pressure is considered to be in the
”high” or ”severe” range, the chances of benefiting would now be 26% and 72%,
respectively. See Pearce et al (1998) [64] for similar results for near-nomotensive.
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Fig. 18. Concavity of Gains to Health Spending. A more appropriate regression line
than the one used by OECD should flatten off to the right, even invert to fit the USA.
Credit: Edward Tufte
But consider that (unless one has a special reason against) the iatrogenics
should be safely considered constant for all categories. In the very ill condition,
the benefits are large relative to iatrogenics; in the borderline one, they are small.
This means that we need to focus on high-symptom conditions compare to other
situations in which the patient is not very ill.
A 2012 Cochrane meta-analysis indicated that there is no evidence that treat-
ing otherwise healthy mild hypertension patients with antihypertensive therapy
will reduce CV events or mortality. Makridakis and DiNicolantonio (2014) [65]
found no statistical basis for current hypertension treatment. Rosansky(2012)[?]
found a ”silent killer” in iatrogenics, i.e. hidden risks, matching our illustration
in distribution space in Fig. 17.
Statin example We can apply the method to statins, which appears to have
benefits in the very ill segment that do not translate into milder conditions.
With statin drugs routinely prescribed to lower blood lipids, although the result
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is statistically significant for a certain class of people, the effect is minor. ”High-
risk men aged 30-69 years should be advised that about 50 patients need to be
treated for 5 years to prevent one [cardiovascular] event” (Abramson and Wright,
2007 [67]).
For statins side effects and (more or less) hidden risks, see effects in muscu-
loskeletal harm or just pain, Speed et al. (2012) [68]. For a general assessment,
seeHilton-Jones (2009) [69], Hu, Cheung et al. (2012) [70]. Roberts (2012) [71]
illustrates indirectly various aspects of convexity of benefits, which necessarily
implies harm in marginal cases. Fernandez et al. (2011) [72] shows where clinical
trials do not reflect myopathy risks . Blaha et al. (2012) [73] shows ”increased
risks for healthy patients. Also, Redberg and Katz (2012) [74]; Hamazaki et al.
[75] : ”The absolute effect of statins on all-cause mortality is rather small, if
any.”
Other For a similar approach to pneumonia, File (2013)[76].
Back: Overtreatment (particularly surgery) for lower back conditions is dis-
cussed in McGill (2015) [?]; the iatrogenics (surgery or epidural), Hadler (2009)
[77].
For a discussion of the application of number needed to treat in evidence-
based studies, see Cook et al (1995) [78]. One can make the issue more com-
plicated with risk stratification (integrating the convexity to addition of risk
factors), see Kannel et al (2000) [79].
Doctor’s strikes: There have been a few episodes of hospital strikes, leading
to the cancellation of elective surgeries but not emergency-related services. The
data are not ample (n = 5) , but can give us insights if interpreted in via negativa
manner as it corroborates the broader case that severity is convex to condition.
It is key that there was no increase in mortality (which is more significant than
a statement of decrease). See Cunningham et al. (2008) [80] . See also Siegel-
Itzkovich (2000) [81]. On the other hand, Gruber and Kleiner (2010) [82] show
a different effect when nurses strike. Clearly looking at macro data as in Fig. 18
shows the expected concavity: treatment results are concave to dollars invested
–life expectancy empirically measured includes the results of iatrogenics.
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